Absence of effect of stimulants on the pharmacokinetics of desipramine in children

Pharmacotherapy

Volumn 19, Issue 6, 1999, Pages 746-752

  Cohen, Louise Glassner ^a,b   Prince, Jefferson ^a,b   Biederman, Joseph ^a,b   Wilens, Timothy ^a,b   Faraone, Stephen V ^a,b   Whitt, Sabrina ^a   Mick, Eric ^a   Spencer, Thomas ^a,b   Meyer, Michele C ^a   Polisner, David ^a   Flood, James G ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; DEXAMPHETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHILD; CONTROLLED STUDY; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; PHARMACOKINETICS; RETROSPECTIVE STUDY; TIC;

ADOLESCENT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DESIPRAMINE; DEXTROAMPHETAMINE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MEDICAL RECORDS; METHYLPHENIDATE; RETROSPECTIVE STUDIES;

EID: 0033001618     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.9.746.31539     Document Type: Article

References (56)

1. Wilens TE, Spencer T, Biederman J, Wozniak J, Connor D. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacotherapy. J Am Acad Child Adolesc Psychiatry 1995;34:110-12.
2. Biederman J, Faraone SV, Baldessarini RJ, et al. Predicting desipramine levels in children and adolescents: a naturalistic clinical study. J Am Acad Child Adolesc Psychiatry 1997;36:384-9.
3. Carlson GA, Rapport MD, Kelly KL, Pataki CS. Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: separate and combined effects on behavior and mood. J Child Adolesc Psychopharmacol 1995;5:191-204.
4. Parraga HC, Kelly DP, Parraga MI, Cochran MK, Maxim LT. Combined psychostimulant and tricyclic antidepressant treatment of Tourette's syndrome and comorbid disorders in children. J Child Adolesc Psychopharmacol 1994;4:113-22.
5. Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM. Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 1993;32:1065-72.
6. Rappoport MD, Carlson GA, Kelly KL, Pataki C. Methylphenidate and desipramine in hospitalized children. II. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993;32:333-42.
7. Spencer T, Biederman J, Wilens T, Steingard R, Geist D. Nortriptyline treatment of children with attention deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc 1993;2:205-10.
8. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992;15:191-222.
9. Wilens TE, Biederman J, Baldessarini RJ, Puopolo P, Flood JG. Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 1992; 31:691-8.
10. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T. Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 1993;32:343-9.
11. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents and adults with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:85S-121.
12. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS, Goldblatt A. A double-blind placebo-controlled study of desipramine in the treatment of ADD. II. Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 1989;28:903-11.
13. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-77.
14. Ambrosini PJ, Bianchi MD, Rabinovich H, Elia J. Antidepressant treatments in children and adolescents. II. Anxiety, physical and behavioral disorders. J Am Acad Child Adolesc Psychiatry 1993;32:483-93.
15. Garfinkel BD, Wender PH, Sloman L, O'Neill I. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry 1983;22:343-8.
16. Schachar R, Tannock R, Cunningham C, Corkum PV. Behavioral, situational and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 1997;36:754-63.
17. Tannock R, Ickowicz A, Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1995;34:886-96.
18. Efron D, Jarman F, Barker M. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997;100:662-6.
19. Grob CS, Coyle JT. Suspected adverse methylphenidate-imipramine interactions in children. J Dev Behav Pediatr 1986;7:265-7.
20. Perel JM, Black N, Wharton RN. Inhibition of imipramine metabolism by methylphenidate. Fed Proc 1969;28:418.
21. Wharton RN, Perel JM, Dayton PG, Malitz S. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry 1971;27:1619-25.
22. Zeidenberg P, Perel JM, Kanzler M, Wharton RN, Malitz S. Clinical and metabolic studies with imipramine in man. Am J Psychiatry 1971;127(10):1321-6.
23. Anonymous. Physicians' desk reference. Montvale, NJ: Medical Economics, 1997.
24. McEvoy GK, ed. AHFS 97 drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1997.
25. Gelman CR, Rumack BH, Sayre NK, eds. DRUGDEX system. Englewood, CO: Micromedex, 1997.
26. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. In: Harden W, Rudin W, Molinoff PB, Rall T, eds. Goodman and Gilman's the pharmacologic basis of therapeutics. New York: McGraw-Hill, 1996:431-59.
27. Brosen K, Gram LF. First-pass metabolism of imipramine and desipramine: impact of the sparetine oxidation phenotype. Clin Pharmacol Ther 1988;43:400-6.
28. Gelman CR, Rumack BH, Sayre NK, eds. DRUGDEX System. Englewood, CO: Micromedex, 1998.
29. May DG. Genetic differences in drug disposition. J Clin Pharmacol 1994;34:881-97.
30. Biederman J. Sudden death in children treated with a tricyclic antidepressant. J Am Acad Child Adolesc Psychiatry 1991;30:495-6.
31. Varley CK, McClellan J. Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1997;36:390-4.
32. Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1491-501.
33. Cohen LG, Biederman J, Wilens T, et al. Desipramine clearance in children and adolescents: absence of effect of development and gender. J Am Acad Child Adolesc Psychiatry 1998;38:79-85.
34. Puopolo PR, Volpicelli SA, Johnson D, Flood JG. Emergency toxicology testing of basic drugs in serum by liquid chromatography with photodiode array detection. Clin Chem 1991;37:2123-30.
35. Milsap RL, Hill MR, Szefler SJ. Special pharmacokinetic considerations in children. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992:10-1-10-32.
36. Rodman JH. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. J Adolesc Health 1994;15:654-62.
37. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Decker, 1982.
38. Sallee FR, Pollock FR. Clinical pharmacokinetic of imipramine and desipramine. Clin Pharmacokinet 1990;18:346-64.
39. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
40. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996;16:267-72.
41. Shader RJ, von Moltke LL, Harmatz JS, Greenblatt DJ. The clinician and drug interactions: an update. J Clin Psychopharmacol 1996;16:197-201.
42. von Moltke, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine in comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
43. Patrick KS, Mueller C, Gualtieri T, Breese GR. Pharmacokinetics and actions of methylphenidate. In: Meltzer H, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:1378-95.
44. Srinivas NR, Hubbard JW, Quin D, Korchinsky ED, Midha KK. Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:213-20.
45. Volkow ND, Wang GJ, Gatley SJ, et al. Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. Psychopharmacology 1996;123:26-33.
46. Anggard E, Jonsson LE, Hogmark AL, Gunne LM. Amphetamine metabolism in amphetamine psychosis. Clin Pharmacol Ther 1973;14:870-80.
47. Cho AK, Wright J. Pathways of metabolism of amphetamine and related compounds. Life Sci 1978;22:363-72.
48. Koyama E, Tanaka T, Chiba K, et al. Steady state plasma concentrations of imipramme and desipramine in relation to s-mephenytoin 4'hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 1996;16:286-93.
49. Koyama E, Chiba K, Tani M, Ishizaki T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of s-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 1997;281:1199-1210.
50. Brosen K. Recent advances in hepatic oxidation. Clin Pharmacokinet 1990;18:220-39.
51. Sproule BA, Naranjo CA, Bremner KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
52. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
53. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin North Am 1997;44:55-77.
54. Rudorfer MV, Potter WZ. Pharmacokinetics of antidepressants. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:1353-63.
55. Dahl ML, Iselius L, Alm C, et al. Polymorphic 2-hydroxylation of desipramine: a population and family study. Eur J Clin Pharmacol 1993;44:445-50.
56. Cohen J. Statistical power analysis for behavioral sciences, 2nd ed., Hillsdale, NJ: Lawrence Earlbaum, 1988.